Fast facts:
Gespeichert in:
| Beteilige Person: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Schriftenreihe: | Fast facts
|
| Schlagwörter: | |
| Links: | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1647323 |
| Abstract: | "Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies.This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes:- the new IMWG SLiM CRAB criteria- the latest advances in diagnostic tests and imaging- cytogenetics and genetic profiling- induction therapy prior to SCT- new lenalidomide- and bortezomib-based regimens- second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments.This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice." -- from website ebook |
| Umfang: | 1 Online-Ressource |
| ISBN: | 1910797383 9781910797389 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV048279206 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220610s2017 xx o|||| 00||| eng d | ||
| 020 | |a 1910797383 |q (electronic bk.) |9 1910797383 | ||
| 020 | |a 9781910797389 |q (electronic bk.) |9 9781910797389 | ||
| 035 | |a (OCoLC)1012500943 | ||
| 035 | |a (DE-599)BVBBV048279206 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 100 | 1 | |a Ramasamy, Karthik |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Fast facts |c Karthik Ramasamy, Sagar Lonial |
| 264 | 0 | |a OXFORD |b HEALTH Press |c 2017 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Fast facts | |
| 505 | 8 | |a Epidemiology and etiology Predisposing conditions associated with MM -- Pathophysiology of MM and MGUS -- Diagnosis, staging and monitoring of multiple myeloma -- Genetics and multiple myeloma -- Treatment of newly diagnosed multiple myeloma -- Stem cell transplantation in multiple myeloma -- Relapsed and refractory multiple myeloma -- Bone disease and renal complications -- AL amyloidosis -- Rare plasma cell dyscrasias -- Supportive care | |
| 520 | 3 | |a "Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies.This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes:- the new IMWG SLiM CRAB criteria- the latest advances in diagnostic tests and imaging- cytogenetics and genetic profiling- induction therapy prior to SCT- new lenalidomide- and bortezomib-based regimens- second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments.This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice." -- from website ebook | |
| 650 | 4 | |a Multiple Myeloma | |
| 650 | 4 | |a Myélome multiple | |
| 650 | 7 | |a HEALTH & FITNESS |2 Diseases | |
| 650 | 7 | |a MEDICAL |2 Clinical Medicine | |
| 650 | 7 | |a MEDICAL |2 Diseases | |
| 650 | 7 | |a MEDICAL |2 Evidence-Based Medicine | |
| 650 | 7 | |a MEDICAL |2 Internal Medicine | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Multiple myeloma | |
| 653 | 6 | |a Electronic books | |
| 856 | 4 | 0 | |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1647323 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-4-EOAC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033659371 | |
Datensatz im Suchindex
| _version_ | 1818989574838288384 |
|---|---|
| any_adam_object | |
| author | Ramasamy, Karthik |
| author_facet | Ramasamy, Karthik |
| author_role | aut |
| author_sort | Ramasamy, Karthik |
| author_variant | k r kr |
| building | Verbundindex |
| bvnumber | BV048279206 |
| collection | ZDB-4-EOAC |
| contents | Epidemiology and etiology Predisposing conditions associated with MM -- Pathophysiology of MM and MGUS -- Diagnosis, staging and monitoring of multiple myeloma -- Genetics and multiple myeloma -- Treatment of newly diagnosed multiple myeloma -- Stem cell transplantation in multiple myeloma -- Relapsed and refractory multiple myeloma -- Bone disease and renal complications -- AL amyloidosis -- Rare plasma cell dyscrasias -- Supportive care |
| ctrlnum | (OCoLC)1012500943 (DE-599)BVBBV048279206 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02762nam a2200445 c 4500</leader><controlfield tag="001">BV048279206</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220610s2017 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1910797383</subfield><subfield code="q">(electronic bk.)</subfield><subfield code="9">1910797383</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781910797389</subfield><subfield code="q">(electronic bk.)</subfield><subfield code="9">9781910797389</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1012500943</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048279206</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ramasamy, Karthik</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fast facts</subfield><subfield code="c">Karthik Ramasamy, Sagar Lonial</subfield></datafield><datafield tag="264" ind1=" " ind2="0"><subfield code="a">OXFORD</subfield><subfield code="b">HEALTH Press</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Fast facts</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Epidemiology and etiology Predisposing conditions associated with MM -- Pathophysiology of MM and MGUS -- Diagnosis, staging and monitoring of multiple myeloma -- Genetics and multiple myeloma -- Treatment of newly diagnosed multiple myeloma -- Stem cell transplantation in multiple myeloma -- Relapsed and refractory multiple myeloma -- Bone disease and renal complications -- AL amyloidosis -- Rare plasma cell dyscrasias -- Supportive care</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">"Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies.This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes:- the new IMWG SLiM CRAB criteria- the latest advances in diagnostic tests and imaging- cytogenetics and genetic profiling- induction therapy prior to SCT- new lenalidomide- and bortezomib-based regimens- second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments.This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice." -- from website ebook</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Myeloma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Myélome multiple</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="2">Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="2">Clinical Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="2">Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="2">Evidence-Based Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="2">Internal Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple myeloma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple myeloma</subfield></datafield><datafield tag="653" ind1=" " ind2="6"><subfield code="a">Electronic books</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1647323</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EOAC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033659371</subfield></datafield></record></collection> |
| id | DE-604.BV048279206 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T19:40:39Z |
| institution | BVB |
| isbn | 1910797383 9781910797389 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033659371 |
| oclc_num | 1012500943 |
| open_access_boolean | 1 |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource |
| psigel | ZDB-4-EOAC |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| record_format | marc |
| series2 | Fast facts |
| spelling | Ramasamy, Karthik Verfasser aut Fast facts Karthik Ramasamy, Sagar Lonial OXFORD HEALTH Press 2017 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Fast facts Epidemiology and etiology Predisposing conditions associated with MM -- Pathophysiology of MM and MGUS -- Diagnosis, staging and monitoring of multiple myeloma -- Genetics and multiple myeloma -- Treatment of newly diagnosed multiple myeloma -- Stem cell transplantation in multiple myeloma -- Relapsed and refractory multiple myeloma -- Bone disease and renal complications -- AL amyloidosis -- Rare plasma cell dyscrasias -- Supportive care "Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies.This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes:- the new IMWG SLiM CRAB criteria- the latest advances in diagnostic tests and imaging- cytogenetics and genetic profiling- induction therapy prior to SCT- new lenalidomide- and bortezomib-based regimens- second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments.This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice." -- from website ebook Multiple Myeloma Myélome multiple HEALTH & FITNESS Diseases MEDICAL Clinical Medicine MEDICAL Diseases MEDICAL Evidence-Based Medicine MEDICAL Internal Medicine Multiple myeloma Electronic books https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1647323 Verlag kostenfrei Volltext |
| spellingShingle | Ramasamy, Karthik Fast facts Epidemiology and etiology Predisposing conditions associated with MM -- Pathophysiology of MM and MGUS -- Diagnosis, staging and monitoring of multiple myeloma -- Genetics and multiple myeloma -- Treatment of newly diagnosed multiple myeloma -- Stem cell transplantation in multiple myeloma -- Relapsed and refractory multiple myeloma -- Bone disease and renal complications -- AL amyloidosis -- Rare plasma cell dyscrasias -- Supportive care Multiple Myeloma Myélome multiple HEALTH & FITNESS Diseases MEDICAL Clinical Medicine MEDICAL Diseases MEDICAL Evidence-Based Medicine MEDICAL Internal Medicine Multiple myeloma |
| title | Fast facts |
| title_auth | Fast facts |
| title_exact_search | Fast facts |
| title_full | Fast facts Karthik Ramasamy, Sagar Lonial |
| title_fullStr | Fast facts Karthik Ramasamy, Sagar Lonial |
| title_full_unstemmed | Fast facts Karthik Ramasamy, Sagar Lonial |
| title_short | Fast facts |
| title_sort | fast facts |
| topic | Multiple Myeloma Myélome multiple HEALTH & FITNESS Diseases MEDICAL Clinical Medicine MEDICAL Diseases MEDICAL Evidence-Based Medicine MEDICAL Internal Medicine Multiple myeloma |
| topic_facet | Multiple Myeloma Myélome multiple HEALTH & FITNESS MEDICAL Multiple myeloma |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1647323 |
| work_keys_str_mv | AT ramasamykarthik fastfacts |